Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
CeriBell, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 2, 2026 at 9:00 a.m. Pacific Time. Investors will elect two Class II directors, Josef Parvizi and Rebecca Robertson, to new three-year terms and ratify PricewaterhouseCoopers LLP as independent auditor for 2026.
Only holders of the 37,872,491 common shares outstanding as of April 6, 2026 may vote, either online during the meeting or by proxy in advance. The company outlines detailed governance practices, director and executive pay, related-party consulting with co‑founder Dr. Parvizi, and change‑in‑control severance protections for senior executives.
Ceribell, Inc. director and CEO Xingjuan Chao exercised stock options and sold shares in a planned trade. On April 6, 2026, she exercised options for 25,000 shares of Common Stock at $4.70 per share and sold 39,000 shares at a weighted average price of $18.40 per share pursuant to a Rule 10b5-1 trading plan. After these transactions, she holds 850,347 shares directly and 369,088 shares indirectly through the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership beyond her pecuniary interest.
CBLL: A Form 144 notice lists proposed and recent sales of Common stock by an affiliated holder. The filing shows proposed sales of 39,000 shares and earlier transactions including 39,000, 2,084, and 39,000 share entries with cash values recorded. Transactions are labeled as stock option exercises and issuer-related sales.
Ceribell, Inc. reported that President and CEO Chao Xingjuan received equity compensation awards. She was granted a stock option for 162,592 shares of common stock at an exercise price of $18.50 per share, expiring on April 1, 2036, vesting quarterly starting on May 20, 2026. She also received a grant of 97,555 shares of common stock in the form of restricted stock units. Following these awards, she directly holds 864,347 shares of common stock and has an additional 369,088 shares held indirectly through the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership except for her pecuniary interest.
Blumberg Scott reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported equity compensation awards. He received a stock option to buy 51,227 shares of common stock at $18.50 per share, expiring on April 1, 2036, and a grant of 30,736 restricted stock units. Following the common stock grant, his direct common stock holdings increased to 149,070 shares. The option shares vest on each quarterly anniversary from May 20, 2026, as long as he remains in an employment or service relationship with Ceribell, making these routine, service-based compensation awards rather than open-market purchases.
Foehr David reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. senior vice president of finance and principal accounting officer David Foehr reported equity compensation awards. He received a grant of options to buy 36,750 shares of common stock at $18.50 per share, expiring on April 1, 2036, and 22,050 restricted stock units.
The option shares will vest on each quarterly anniversary from May 20, 2026, as long as he continues his service with the company on each vesting date. Following these grants, Foehr directly holds 39,600 shares of common stock. These are compensation-related awards, not open-market purchases or sales.
Manni Joseph S. reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. reported that Chief Revenue Officer Joseph S. Manni received equity compensation on April 1, 2026. He was granted a stock option to buy 51,227 shares of common stock at $18.50 per share, expiring on April 1, 2036, and a separate grant of 30,736 shares of common stock as restricted stock units. The option vests on each quarterly anniversary from May 20, 2026, subject to his continued service. After these awards, he directly owns 57,669 shares of common stock.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported a mix of option exercises, stock sales, and new equity awards. On April 1, he exercised stock options for a total of 11,112 shares of common stock at exercise prices of $2.24 and $4.70 per share, then sold the same 11,112 shares in open-market transactions at prices around $18.53–$18.58. The filing notes these trades were made under a Rule 10b5-1 trading plan. Woo also received new grants: 51,227 stock options at an exercise price of $18.50 and 30,736 restricted stock units, bringing his direct common stock holdings to 197,648 shares after the transactions.
CBLL reported proposed resale transactions under a Form 144. The filing lists securities to be sold on 04/01/2026 arising from option grants dated 07/07/2021 (1,472 shares) and 02/16/2023 (9,640 shares). The filing also records prior open-market sales by Raymond Woo: 01/02/2026 (11,112 shares for $235,228.09), 02/02/2026 (11,112 shares for $228,408.70), 03/02/2026 (11,112 shares for $202,831.12), and 02/23/2026 (705 shares for $13,955.12). The broker on the notice is Fidelity Brokerage Services LLC.